Infectious Disease Response

Vaccines for a healthier society Next Generation Vaccine Development and Commercial Production to Defeat Future Pandemic Viruses

Biopharma Research Centre is conducting research and development for new and improved vaccines to proactively respond to infectious diseases like the COVID-19 pandemic.
Biopharma Research Centre has been preparing for a business expansion into the development and production of vaccine since the start of the ongoing COVID-19 outbreak as a response to the current, and potential future, viral pandemics. Since when COVID-19 was in full swing, the company has prepared its facilities, manpower, and project experience for the vaccine business. In addition, Biopharma Research Centre has been concurrently researching a First-in-Class vaccine, which is being developed independently.

Vaccine development for unmet diseases

Continuous research for developing new vaccines Developing vaccines to prevent unmet diseases and thereby preventing the occurrence of hard-to-treat conditions like cancer

Biopharma Research Centre is developing vaccines for the prevention of hard-to-treat unmet diseases. We are not only focused on developing treatments for challenging conditions like cancer but also seeking solutions to prevent such diseases. Through open innovation and various collaborations, we look forward to the convergence of our proprietary science with new ideas and scientific advancements.